| Literature DB >> 24591352 |
Hiroshi Ono1, Noriko Motoi, Hiroko Nagano, Eisaku Miyauchi, Masaru Ushijima, Masaaki Matsuura, Sakae Okumura, Makoto Nishio, Tetsuro Hirose, Naohiko Inase, Yuichi Ishikawa.
Abstract
Small-cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. To identify accurate predictive biomarkers and effective therapeutic modalities, we focus on a long noncoding RNA, Hox transcript antisense intergenic RNA (HOTAIR), and investigated its expression, cellular functions, and clinical relevance in SCLC. In this study, HOTAIR expression was assessed in 35 surgical SCLC samples and 10 SCLC cell lines. The efficacy of knockdown of HOTAIR by siRNA transfection was evaluated in SBC-3 cells in vitro, and the gene expression was analyzed using microarray. HOTAIR was expressed highly in pure, rather than combined, SCLC (P = 0.012), that the subgroup with high expression had significantly more pure SCLC (P = 0.04), more lymphatic invasion (P = 0.03) and more relapse (P = 0.04) than the low-expression subgroup. The knockdown of HOTAIR in SBC-3 cells led to decreased proliferation activity and decreased invasiveness in vitro. Gene expression analysis indicated that depletion of HOTAIR resulted in upregulation of cell adhesion-related genes such as ASTN1, PCDHA1, and mucin production-related genes such as MUC5AC, and downregulation of genes involved in neuronal growth and signal transduction including NTM and PTK2B. Our results suggest that HOTAIR has an oncogenic role in SCLC and could be a prognostic biomarker and therapeutic target.Entities:
Keywords: HOTAIR; invasiveness; lincRNA; proliferation; small-cell lung cancer
Mesh:
Substances:
Year: 2014 PMID: 24591352 PMCID: PMC4101754 DOI: 10.1002/cam4.220
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Comparisons of clinicopathological factors of all SCLC patients enrolled (n = 35) and those with high- and low expression of HOTAIR
| All cases, examined ( | Cases with high- | Cases with low- | |||||
|---|---|---|---|---|---|---|---|
| Factors | % | % | % | ||||
| Age (mean ± SD) | 65.8 ± 6.60 | 63.3 ± 6.70 | 67.1 ± 6.30 | 0.10 | |||
| Gender | |||||||
| M | 25 | 71.4 | 9 | 75.0 | 16 | 69.6 | 0.53 |
| F | 10 | 28.6 | 3 | 25.0 | 7 | 30.4 | |
| Cumulative smoking (pack-years) | 52 ± 31 | 52 ± 19 | 52 ± 36 | 0.96 | |||
| Chemotherapy type | |||||||
| NAC − AC− | 3 | 8.60 | 1 | 8.33 | 2 | 8.70 | |
| NAC + AC− | 3 | 8.60 | 0 | 0 | 3 | 13.0 | |
| NAC − AC+ | 23 | 65.7 | 8 | 66.7 | 15 | 65.2 | |
| NAC + AC+ | 6 | 17.1 | 3 | 25.0 | 3 | 13.0 | |
| Regimen | |||||||
| NAC( | CDDP + VP16 (8) | 22.9 | 3 | 25.0 | 5 | 21.7 | |
| CDDP + DOC (1) | 2.90 | 0 | 0 | 1 | 4.35 | ||
| AC( | CDDP + VP161 (22) | 62.9 | 10 | 83.3 | 12 | 52.2 | |
| CBDCA + VP162 (4) | 11.4 | 0 | 0 | 4 | 17.4 | ||
| Mix; 1 and 2 (3) | 8.60 | 1 | 8.33 | 2 | 8.70 | ||
| Histological type (SCLC) | |||||||
| Pure | 24 | 68.6 | 11 | 91.7 | 13 | 56.5 | 0.04 |
| Combined | 11 | 31.4 | 1 | 8.33 | 10 | 43.5 | |
| With Ad (5) | 45.5 | 0 | 0 | 5 | 50.0 | ||
| With LCC (2) | 18.2 | 0 | 0 | 2 | 20.0 | ||
| With LCNEC (4 | 36.4 | 1 | 100 | 2 | 20.0 | ||
| With others (1) | 9.10 | 0 | 0 | 1 | 10.0 | ||
| Operation (SCLC) | |||||||
| Partial resection | 3 | 8.60 | 1 | 8.33 | 2 | 8.70 | |
| Segmentectomy | 0 | 0 | 0 | 0 | 0 | 0 | |
| Lobectomy (1 lobe) | 27 | 77.1 | 10 | 83.3 | 17 | 73.9 | |
| Lobectomy + partial resection | 1 | 2.90 | 1 | 8.33 | 0 | 0 | |
| Lobectomy (2 lobes) | 2 | 5.70 | 0 | 0 | 2 | 8.70 | |
| Pneumectomy | 2 | 5.70 | 0 | 0 | 2 | 8.70 | |
| Pathological stage | |||||||
| 1a | 11 | 31.4 | 1 | 8.33 | 10 | 43.5 | |
| 1b | 4 | 11.4 | 2 | 16.7 | 2 | 8.70 | |
| 2a | 7 | 20.0 | 3 | 25.0 | 4 | 17.4 | |
| 2b | 2 | 5.70 | 0 | 0 | 2 | 8.70 | |
| 3a | 10 | 28.6 | 6 | 50.0 | 4 | 17.4 | |
| 3b | 1 | 2.90 | 0 | 0 | 1 | 4.35 | |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Invasion (microscopic) | |||||||
| Vascular invasion | 29 | 82.9 | 9 | 75.0 | 20 | 87.0 | 0.33 |
| Lymphatic invasion | 20 | 57.1 | 10 | 83.3 | 10 | 43.5 | 0.03 |
| Relapse | 15 | 42.9 | 8 | 66.7 | 7 | 30.4 | 0.04 |
| Brain (6) | 40.0 | 4 | 50.0 | 2 | 28.6 | ||
| Lung (2) | 13.3 | 2 | 25.0 | 0 | 0 | ||
| Mediastinal LNs (4) | 26.7 | 3 | 37.5 | 1 | 14.3 | ||
| Stomach (1) | 6.70 | 0 | 0 | 1 | 14.3 | ||
| Liver (3) | 20.0 | 1 | 12.5 | 2 | 28.6 | ||
| Adrenal gl. (2) | 5.70 | 1 | 12.5 | 1 | 14.3 | ||
| Others (pleural eff.) (1) | 6.70 | 0 | 0 | 1 | 14.3 | ||
| Survival | |||||||
| Alive | 19 | 54.3 | 5 | 41.7 | 14 | 60.9 | |
| Dead | 16 | 45.7 | 7 | 58.3 | 9 | 39.1 | |
| Lung cancer (11) | 68.7 | 6 | 85.7 | 5 | 55.6 | ||
| Other malignancy (2) | 12.5 | 1 | 14.3 | 1 | 11.1 | ||
| Other disease (2) | 12.5 | 0 | 0 | 2 | 22.2 | ||
| Unknown (1) | 6.30 | 0 | 0 | 1 | 11.1 | ||
| DSS (mean ± SD) | 45.3 ± 35.7 mos. | 38.1 ± 27.2 mos | 49.0 ± 39.5 mos | ||||
| RFS/DFS (SCLC) (mean ± SD) | 40.9 ± 38.5 mos. | 30.8 ± 30.7 mos | 46.3 ± 41.6 mos | ||||
SCLC, small-cell lung cancer; smoking index, a product of number of cigarettes per day by duration in years; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; CDDP, cisplatin; CBDCA, carboplatin; VP-16, etoposide; DOC, docetaxel; Ad, adenocarcinoma; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; LNs, lymph nodes; DSS, disease-specific survival; RFS, relapse-free survival; DFS, disease-free survival.
P < 0.05.
Figure 1HOTAIR expression levels assessed by quantitative RT-PCR in 35 SCLC and normal tissues. Comparisons between all the tumors (n = 35) and normal tissues (n = 15) (A), pure (n = 24) and combined (n = 11) SCLC (B) (P = 0.009), pure SCLC and normal (C), and between pure SCLC with adjuvant chemotherapy and no neoadjuvant chemotherapy (n = 18) and normal (D) (P = 0.012) were made. HOTAIR was highly expressed in pure SCLC than combined SCLC and normal tissues.
Figure 2HOTAIR expression levels in SCLC and survival curves by HOTAIR expression. (A) HOTAIR expression in 35 SCLC and a reference level (HOTAIR/ACTB ratio = 1.368). (B and C) The Kaplan–Meier DSS curves and RFS/DFS curves, respectively, according to HOTAIR levels in pure-SCLC cases with adjuvant chemotherapy and no neoadjuvant chemotherapy (n = 18). Note that there was a tendency to poor prognosis in the high-expression group for the RFS/DFS of these groups (P = 0.086). For abbreviations, see text.
Figure 3Expression of HOTAIR in cell lines and xenografts of SCLC. (A) Relative expression levels normalized to GAPDH. The SBC-3 line showed particularly high expression. (B) Comparisons in five SCLC cell lines with higher expression than normal cells. For abbreviations, see text.
Figure 4HOTAIR abundance, cellular proliferation and invasiveness in SBC-3 cells with transfection of siRNA and of siGFP. (A) The graph showed the HOTAIR/GAPDH ratio. #1–3 siHOTAIRs successfully reduced the expression levels. (B), #1 siHOTAIR-transfected cells reduced their ability of proliferation after 72 h, although #2, #3 siHORAIR did not reduce. (C) Invasiveness was assessed by % invasion and invasion index according to manufactures' protocol. In #1 siHOTAIR-transfected cells, almost 30% reduction of matrigel invasiveness was seen, whereas #2 and #3 siHOTAIR did not reduce invasiveness.